Yonsei Med J.  1998 Dec;39(6):541-545. 10.3349/ymj.1998.39.6.541.

A mutation in QRDR in the ParC subunit of topoisomerase IV was responsible for fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae

Affiliations
  • 1Department of Biology, Seoul Women's University, Seoul, Korea. yhlee@swift2.swu. ac.kr
  • 2Department of Pediatrics, Seoul Women's University, College of Medicine, Seoul National University, Seoul, Korea.

Abstract

Forty-one strains of Streptococcus pneumoniae were isolated at Seoul National University Children's Hospital from 1991 to 1997. Isolates were divided into six groups based on MICs of three quinolones, ciprofloxacin, ofloxacin and norfloxacin. Sequencing showed that the isolates which were intermediately resistant to three quinolones or resistant to at least one kind of quinolone had one missense mutation, Lys137-->Asn(AAG-->AAT) substitution in the ParC subunit of topoisomerase IV without additional mutation in QRDR of the GyrA subunit of DNA gyrase. In conclusion, the ParC subunit of DNA topoisomerase IV is the primary target site for fluoroquinolone in S. pneumoniae and Lys137-->Asn substitution renders the quinolone resistance in S. pneumoniae.

Keyword

S. pneumoniae; fluoroquinolone resistance; ParC; GyrA; DNA gyrase; topoisomerase IV; QRDR

MeSH Terms

DNA Topoisomerase (ATP-Hydrolysing)/genetics*
Drug Resistance, Microbial/genetics*
Human
Isoenzymes/genetics*
Mutation/genetics*
Quinolones*
Streptococcus pneumoniae/genetics
Full Text Links
  • YMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr